SAMSUNG BIOLOGICS

SAMSUNG BIOLOGICS is a premier contract development and manufacturing organization (CDMO) specializing in end-to-end biopharmaceutical services. Founded in 2011, the company provides comprehensive solutions including cell line development, process development, and clinical manufacturing. Operating with a workforce of 1,000-5,000 employees, SAMSUNG BIOLOGICS maintains a robust technical infrastructure to support global biopharmaceutical partners. Their service portfolio encompasses aseptic filling, lyophilization, and advanced analytical testing, ensuring compliance with rigorous quality assurance standards. Meet SAMSUNG BIOLOGICS's team to explore the expertise driving their operational excellence.

The company’s technical capabilities extend to the research and commercialization of biosimilar drugs, as well as the development and manufacturing of antibody-drug conjugates. SAMSUNG BIOLOGICS leverages a sophisticated technology platform to manage mammalian and mRNA product manufacturing, catering to complex client requirements in the healthcare sector. By integrating discovery through commercial-scale production, they provide a seamless transition for biopharmaceutical products from laboratory testing to market entry. Their commitment to quality-driven processes and biosafety is central to their role as a leading global service provider.

With three strategic locations, SAMSUNG BIOLOGICS maintains a significant footprint in the international pharmaceutical industry. The firm’s focus on CMC (Chemistry, Manufacturing, and Controls) and R&D services positions it as a critical partner for biotech firms seeking scalable manufacturing services. By prioritizing safety and high-quality bioprocess management, the company continues to expand its influence across South Korea, Europe, and the United States, reinforcing its status as a key player in the global biopharmaceutical supply chain.